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Abstract
Current strategies for the treatment of Alzheimer's disease (AD) involve tackling the formation or
clearance of the amyloid-beta peptide (Aβ) and/or hyper-phosphorylated tau, or the support and
stabilization of the remaining neuronal networks. However, as we gain a clearer idea of the large
number of molecular mechanisms at work in this disease, it is becoming clearer that the treatment
of AD should take a combined approach of dealing with several aspects of the pathology. The
concept that we also need to protect specific sensitive targets within the cell should also be
considered. In particular the role of protecting the function of a specific mitochondrial protein,
amyloid binding alcohol dehydrogenase (ABAD), will be the focus of this review. Mitochondrial
dysfunction is a well-recognized fact in the progression of AD, though until recently the
mechanisms involved could only be loosely labeled as changes in `metabolism'. The discovery
that Aβ can be present within the mitochondria and specifically bind to ABAD, has opened up a
new area of AD research. Here we review the evidence that the prevention of Aβ binding to
ABAD is a drug target for the treatment of AD.
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INTRODUCTION
The past decade has seen many advances in dementia research towards the development of
new innovative therapies for Alzheimer's disease (AD). However, these efforts have yet to
lead to a major breakthrough in AD treatment. The AD research community still debates the
relative significance of tau and amyloid-beta (Aβ) pathologies in the progression of this
disease and with regard to the latter whether this is intracellular or extracellular [1]. There is
also debate concerning the relative importance of “nature and nurture” with regard to active
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research programs using genome wide analysis to identify genetic risk factors versus
changes in lifestyle [2]. The truth is likely to be a combination of all of these events. What is
therefore clear is that a future treatment for AD will not consist of a one-drug therapy, but
will include a combination of different approaches.
Despite the best efforts of the pharmaceutical industry, some in the science community are
now seeking a radical rethink in how drugs to treat this disease will be developed. In
particular, many new and recent attempts can become thwarted in the early stages of
development when trying to solve all the technical issues of target-based drug design in one
go [3]. Instead, methods such as lead-oriented synthesis of new compounds have recently
been suggested as more promising alternative routes [4]. This is accompanied by an
increasing number of authors stressing the importance of understanding the detailed
molecular mechanism of action of a potential new drug and of using appropriate phenotypic
assays in its validation and design [5]. It could be argued that we are only starting to
understand the molecular changes that are occurring within neurons in AD. However, we
would predict that future treatments will consist of targeting three aspects:
(i) The formation or clearance of Aβ and/or hyper-phosphorylated tau; though
debate rages on whether dismantling a protein aggregate would be a good thing,
and as yet targeting the production or synthesis of these toxic proteins has
proven to be difficult [6–8].
ii) The support and stabilization of the remaining neuronal networks. This includes
the current drug therapies such as cholinesterase inhibitors and memantine [9].
iii) The protection of specific sensitive targets. By identifying the particularly
important sensitive targets in AD, it may be possible to protect them against the
toxicities of Aβ and/or tau.
It is in regard to this last point which provides the setting of this review and in particular
leads to the role of protecting a specific mitochondrial protein (amyloid-binding alcohol
dehydrogenase (ABAD)) as an example of how the new criteria of drug-design can be
applied.
Mitochondrial dysfunction is a well-recognized fact in the progression of AD, though until
recently the mechanisms involved could be loosely labeled as changes in `metabolism' [10].
It is now apparent that there are subtle and complex molecular factors at work in
mitochondria and of particular importance is the fact that the observed mitochondrial
damage is potentially reversible, as has been shown in various animal models [11–13]. It is
also now known that not all mitochondria are created equal and as such synaptic
mitochondria have been found to be more vulnerable to the stresses associated with AD
pathology [14–18].
The function of mitochondria is to create energy and provide homeostasis and so energy
production and metabolism have been known for many years to be defective in AD
pathology [10, 19]. Changes in mitochondrial enzymes involved in the electron transport
chain and citric acid cycle have been previously noted by many groups [9, 20–22] and as
such these observations fit with the idea of mitochondrial dysfunction and oxidative stress as
central aspects of AD pathogenesis [23]. Accordingly, clinicians have used the metabolism
of glucose as a particular useful method of detecting specific metabolic changes in the brains
of AD patients [24, 25]. In addition, although administration of simple antioxidants, such as
vitamin E, in the management of AD has so far been unsuccessful [26], the development and
application of mitochondria-targeted antioxidant compounds has emerged as a promising
approach for the treatment of neurodegenerative diseases [13, 27]. However, until recently
what has not been so clear are the molecular mechanisms causing mitochondrial damage.
Borger et al. Page 2













Recent research efforts have introduced the concept that the accumulation of Aβ inside the
cells and specifically in mitochondria might be a likely explanation for the observed
mitochondrial damage in AD (reviewed in [28]). The accumulation of intracellular Aβ (of
both Aβ(1–40) and Aβ(1–42)) has been shown several times [29–37] and indeed, unlike
extracellular plaques, has been shown to correlate with the disease progression [38, 39]. In
2004, it was published that Aβ could be found inside mitochondria in both animal models
and significantly also in human AD sufferers [34]. This therefore begs the question what is
the intra-mitochondrial Aβ doing? At present two molecular binding targets for Aβ have
been identified within mitochondria, namely ABAD and cyclophilin D [15, 40]. What is
particularly significant about these two proteins, is that both show an increase in expression
levels in AD and at the same time have been shown to bind Aβ with nanomolar affinity [34,
37]. This is in contrast to the changes observed in other mitochondrial proteins involved in
metabolism which have been found to have reduced expression levels and activity in AD
and for which a specific interaction with Aβ has not been described.
AMYLOID BINDING ALCOHOL DEHYDROGENASE
It was the identification of an intracellular protein via originally a yeast two hybrid screen
for Aβ binding molecules, that opened up a new area of mitochondria focused AD research
[41]. From this initial screen the mitochondrial protein ABAD has subsequently been shown
to bind Aβ via a plethora of different techniques ranging from biophysical approaches
(NMR, SPR) through to immunoprecipitation experiments from both AD transgenic mice
and human AD brains [34, 42, 43], where ABAD expression levels have also been found to
be up-regulated [41]. Initial studies indicated that the binding of Aβ could occur at
nanomolar affinity; however, it was not until micromolar levels of Aβ were reached, that
changes in ABAD activity were also observed [44, 45]. ABAD contains a Rossman fold
[46] for the binding of nucleotides and it has been shown to be able to catalyze, with the
help of NAD+/NADH, the reduction of aldehydes and ketones and oxidation of alcohols for
energy production utilizing different substrates. As reviewed by Muirhead et al. [47], these
substrates range from simple alcohols and amino acid metabolites [48] through to fatty acid
metabolites and steroids [28]. Of interest, deficient turnover of one of these substrates,
isoleucine, due to inherited point mutations in ABAD, is associated with neurological
abnormalities [48].
ABAD activity can be manipulated in two ways, under conditions of stress (it increases)
[49] or in the presence of Aβ (it decreases) [34, 50]. With regard to the latter, the change in
activity due to the binding of Aβ to ABAD has been previously presented as a rather digital
response, that is, as Aβ binds to ABAD it switches its activity off with respect to a number
of simple substrates [44, 45]. However, recent data from our laboratories suggests that this
rather digital view may be an over simplification (FGM, unpublished data). An up-
regulation of ABAD has been suggested to have protective effects in models of
Parkinsonism [51] and metabolic stress [49]. However, in AD models, it has been shown
that the presence of active ABAD [34, 52], but not an inactive mutant of the enzyme [45],
can in fact enhance mitochondrial dysfunction and oxidative stress in vitro [34, 41] and in
vivo [34, 52] (Fig. 1). Moreover, studies have now identified additional consequences of Aβ
binding to ABAD in living organisms. Specifically, there are a number of genes that are
switched on and appear to be controlled by the binding of Aβ to ABAD. Examples include
the antioxidant protein peroxiredoxin-2 [53] and the presynaptic endocytic protein
endophilin-1 (also referred to as endophilin A1) [54], both of which have been found to be
up-regulated in the human AD brain as well [53, 54]. Other proteins have also been shown
to be increased such as creatine kinase B, and heat shock protein 70 (FGM and SDY
unpublished data) both of which have now been linked by other groups to AD progression
[55–57]. The ability to control the expression of an array of other proteins could suggest that
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it is not a simple question of switching off activity, but potentially that the binding of Aβ to
ABAD causes the enzyme to change its ability to utilize certain substrates, which in turn
would affect other proteins directly or indirectly. It has been challenging to pin point the
exact in vivo substrates of ABAD in the brain, though our recent work suggests that there
are indeed subtle changes in lipid metabolism in response to altered ABAD activity in cells
(FGM and SDY unpublished data).
CONSEQUENCES OF ABAD AND Aβ BINDING
A number of molecular and cellular changes occur after ABAD and Aβ interact within the
mitochondria [28], but as mentioned above, in living organisms it can result in protein
expression changes in the brain. The two best described proteins, peroxiredoxin-2 and
endophilin-1, are examples of the complexity of the biochemical pathways that become
activated in AD and both can be linked to synaptic activity (Fig. 1).
Peroxiredoxin-2 is known to be an antioxidant protein, which has the ability to prevent Aβ
induced toxicity [53]. Its expression has also been shown to be elevated in both transgenic
AD animals and the post-mortem human brain [53]. Peroxiredoxin-2 has further been linked
to the mechanisms at work in the parkinsonian brain [58–60]. However, it would appear that
it is not a simple question of just elevated levels of this protein, as it has been shown that
there is a critical residue that can be phosphorylated (Thr89) which would lead to the
inactivation of the enzyme's activity [59]. This is thought to be the case in the parkinsonian
brain [59], but it remains to be seen whether this is the case in the AD brain, too. Indeed, one
of the kinases known to phosphorylate this residue in peroxiredoxin-2 is CDK5 [59], which
in turn has been shown to have elevated levels of activity in the AD brain [61, 62], thus
suggesting peroxiredoxin-2 may indeed be phosphorylated and therefore inactivated in AD.
In addition, peroxiredoxin-2 activity can also be controlled directly by oxidation [63], for
example induced by the administration of the dopaminergic toxin 6-hydroxydopamine [58]
or S-nitrosylation [60]. Therefore it appears that the actual state of post-translational
modification of this protein in the brain affected by Parkinson's disease or AD, may be an
important aspect.
The second protein that has been shown to be elevated in the AD brain in response to ABAD
binding to Aβ is endophilin-1. This is a member of a family of proteins which together have
an expanding number of functions, ranging from synaptic vesicle endocytosis, mitochondrial
function and receptor trafficking [64]. Specifically, this family of proteins was predicted to
be involved in neurodegenerative diseases [65] prior to them now being shown to be
involved in AD [54], Parkinson's disease [66], spinocerebellar ataxia 2 [67], and
Huntington's disease [64]. In the case of AD, it was the family member endophilin-1 that has
been directly shown to be involved. Initially, it was shown that increased levels of
endophilin-1 can be linked to increased activation levels of the stress kinase c-Jun N-
terminal kinase (JNK) in both HEK293 cells [68] and primary cortical neurons [54] and
increased JNK-activity has been known to be a feature of AD pathology [69]. The activation
by endophilin-1 occurs potentially through a germinal center like kinase (GLK)-mediated
pathway [68]. GLK is part of the germinal center kinases family and their activation is
thought to be via the binding of SH2/SH3 adapter binding proteins which are associated
with membranes [70]. Endophilin-1 fulfills both of these criteria by affecting lipid
membrane curvature for synaptic vesicle formation and by containing a C-terminal SH3
domain [65]. With this in mind, it is interesting to note that endophilin-1 as well as
peroxiredoxin-2 have been identified in the same vesicle complexes as the scaffold protein
Sunday driver/JNK-interacting protein 3 (JIP3) by immunoprecipitation studies on
synaptosomes from the mouse cortex [71]. The recruitment and activation of GLK can lead
to the activation of the MAP3K, MEKK1 [72]. Previous findings indicated that MEKK1
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interacts with inactive MKK4 to form a MEKK1-MKK4 complex. Active MEKK1 can
phosphorylate and activate MKK4 (and/or MKK7), resulting in its dissociation from the
complex. The free and active MKK4 then specifically interacts with JNK. Once activated,
JNK can translocate to the nucleus or other target sites to phosphorylate downstream
effectors, thereby affecting important aspects of neuronal function such as neurite
outgrowth, mitochondrial function, synaptic plasticity and apoptosis (all reviewed in [69]).
This suggests that through recruiting GLK via its SH3-domain, endophilin-1 might be able
to co-localize important components of the JNK-signaling cascade and facilitate its
activation. This might further be influenced by the presence of peroxiredoxin-2 [71], which
has also been implicated in the activation of JNK-signaling in a cancer cell model [73].
However, it is possible that endophilin-1 may have another direct effect on synaptic
signaling as it can lead to the increased probability of glutamate release [74]. This implies
that an elevated level of endophilin-1 at the synapse can interfere with normal
neurotransmitter signaling. Indeed, it is possible to speculate that an increase in endophilin-1
may have different effects in different locations, as endophilin-1 has been found both in the
pre-synaptic neuron [75–77] but also the post-synaptic density [78], where it has recently
been given a role in dendritic development [79]. In either case, the relative presence or
absence of other signaling molecules will determine which pathways endophilin-1 can
influence inside the cell. In addition, the function of endophilin-1 has also been found to be
affected by local levels of calcium [80], which are known to be disturbed in AD [81]. This
coupled with the recent discovery that pre-synaptic mitochondria expressing ABAD and Aβ
are more sensitive than their soma compatriots [14] implies, that spatial localization of these
events could be of paramount importance as they may also influence endophilin-1 function
through altered ABAD activity affecting lipid metabolism or mitochondrial dysfunction and
calcium homeostasis. Therefore, the interaction of ABAD and Aβ within mitochondria is
able to elevate endophilin-1 protein [54] and mRNA expression levels (Yan, unpublished
results). How this occurs is unknown, but it is likely to have far-reaching consequences for
synaptic function (Fig. 2).
EVIDENCE THAT ABAD IS A DRUG TARGET
The specific up-regulation of ABAD in human AD and interaction with Aβ [34, 41] which
caused mitochondrial dysfunction [52] and other cellular effects also present in the human
AD brain [53, 54], suggested that the ABAD-Aβ interaction might be a potential drug target.
Using the knowledge gained from understanding how ABAD and Aβ bind to each other, a
series of publications have now further validated this view. The crystal structure of ABAD
with Aβ bound produced an insight into their interaction. Unfortunately, the exact contact
sites could not be established due to distortion of the crystal structure in this area [34], but it
was found that a region called loop D encompassing residues 92 to 120 was the region of
ABAD that could bind Aβ and this could be confirmed by various biophysical experiments
[34, 82]. However, the most convincing data that this interaction was significant, came from
the ability of a peptide based on the sequence of this region to work as a decoy in vivo (Fig.
2). Initial experiments showed that modifying the decoy peptide by addition of peptide
sequences from the cell-membrane transduction domain of the human immunodeficiency
virus-1 (HIV-1) tat protein [83, 84], enabled the ABAD decoy peptides (ABAD-DP) to cross
cell membranes and prevent Aβ toxicity in neuronal cultures [34, 85]. Others showed that
linking this peptide region with thioredoxin 1 and then expressing the chimeric protein in
cell cultures, also protected against Aβ toxicity [85]. It was then the ability of using
modified decoy peptides in living organisms that introduced the fascinating possibility that
the ABAD and Aβ interaction could be a drug target. Adding a mitochondrial targeting
sequence to the decoy peptide facilitated its localization in mitochondria after intraperitoneal
injection and transport through the blood brain barrier. It was then possible to show in 6
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month old transgenic animals expressing elevated levels of ABAD and Aβ, that the
observed increases in the expression levels of peroxiredoxin-2 and endophilin-1, could be
reversed [53, 54]. Even more significant was the finding that using the same approach, it
was possible to reverse the behavioral changes in these animals as well [11]. Another
important aspect of these studies was, that the reversal of behavioral changes could be
achieved by both purified peptide injected intraperitoneally and also in a transgenic animal
model expressing the ABAD region 92–120 [11]. This approach also showed an additional
potentially protective error; positive effect as the level of mitochondrial Aβ was reduced in
the treated animals which correlated with an increase in the Aβ-degrading enzyme PreP
(presequence peptidase) [11].
Therefore, in keeping with the requirements for a suitable drug target (“ligandability” and
“druggability”) recently reviewed by Hann et al [86], it has been shown by both biochemical
and physiological determinates that preventing Aβ binding to ABAD can be achieved
(ligandability) and has a significant positive effect (druggability). However the question
remains whether it is possible to design drugs around such a complex target.
APPROACHES: BLOOD BRAIN BARRIERS, CELLULAR ASSAYS AND
PEPTIDES
As indicated above, ABAD is a sensitive site in AD that can be protected from its interaction
with Aβ, which could be beneficial in AD treatment. Classically, protein-protein interactions
have been avoided as therapeutic targets because of perceived difficulties in developing
compounds [87]. To overcome the perceived problems, then it is necessary to be
imaginative.
For example, crossing the blood brain barrier is a perennial problem when dealing with
small molecules; however, the studies above have shown that intraperitoneally injected
peptides are capable of crossing the blood brain barrier and targeting the correct site in
animal models [11, 53, 54]. Other recent imaginative work has shown that other approaches
can have the same capability. A study in mice revealed, that modified retroviruses showed
an increased efficiency of gaining access to the central nervous system when mannitol was
peritoneally injected before intravenous administration of the viruses [88]. Another recent
breakthrough has been the use of targeted exosomes, again injected intravenously, which
allowed biological relevant compounds (in this case siRNA) encapsulated in these
membranes, to be successfully delivered into the brain [89]. Therefore there may be new
horizons for getting compounds across the blood brain barrier.
For good reasons, the development of small molecules as drugs is the standard method in
academia [3]. However, coupled to this approach has been the classical method of devising a
high throughput in vitro enzyme assay, but this approach has recently been one of the
pitfalls for the pharmaceutical industry, and so there has been a push to develop more cell
based phenotypic assays [5]. For ABAD and Aβ the ability of the tested compounds to
prevent this interaction has been monitored at the cellular level by measuring the protection
provided by them in terms of for example preserving mitochondrial integrity, cytochrome C
release and respiration [12, 34, 85]. More direct methods may also be possible with the
advent of the first generation of ABAD targeted substrate mimics such as the fluorogenic
cyclohexenylamine naphthalene alcohol (CHANA)-(−) [47, 90], which, under specific
conditions, could be used to measure the prevention of Aβ induced inhibition of ABAD
activity in living cells as a read out for compound testing.
Use of the loop D of ABAD has proven to be successful as described above, but in drug
terms a 40 amino acid peptide (20 amino acids from ABAD, approximately 20 amino acids
Borger et al. Page 6













from targeting sequences) would be thought of as too large a molecule to become a drug.
However, it could be thought of as a template. At present the minimal size of the loop D
ABAD and its constituent parts that provide protection is not known. In addition, it might be
possible to design smaller mitochondrial targeting peptides [91], and also modify the amino
acids as simple peptide isosteres and heterocyclic peptide isosteres to increase rigidity of the
peptidomimetic, or the use of cyclic peptides which increase cellular stability. Indeed, there
are examples of modified peptides that have been produced to act on mitochondrial proteins
such as antamanide, a 10 amino acid cyclic peptide that targets cyclophilin D [92].
However, small molecule compounds that prevent Aβ binding to ABAD can also be
considered as possible. For example, frentizole was identified by an ELISA-based screening
assay, as a novel inhibitor of the ABAD-Aβ interaction, and was subsequently modified
with the production of a novel benzothiazole urea, resulting in a 30-fold improvement in
potency [42]. This compound was found to have potential undesirable immunosuppressive
qualities [42]; however, this approach indicated that it might be possible to develop
pharmacologically active and medically useful compounds targeting ABAD. Fragment-
based drug discovery has been a popular strategy for this used in academia as well as
pharmaceutical industry [3]. Two commonly employed screening technologies in this field
are thermal shift analysis and saturated transfer difference NMR spectroscopy [93–95],
which can identify compounds with millimolar affinity for the target. By grouping
compounds, for example using structure activity relation (SAR) analysis, improved affinities
for the target can then be achieved [93, 96]. Alternatively, fragments can also be combined,
in order to effectively sample the available chemical space as proposed by Hann et al. [86].
Thus, though the ABAD-Aβ interaction is not a classical site for drug therapy, the biology
dictates that this interaction may be a future target (Fig. 3). At the very least, the work that
was inspired from the original yeast two hybrid screen has shown that it is possible to
identify not just new drug targets but also novel biological pathways and events that occur in
neurodegenerative diseases such as AD.
CONCLUSION
Multiple lines of evidence indicate that mitochondrial dysfunction is an early pathological
feature of AD. Aβ can directly and indirectly interfere with mitochondria by affecting
mitochondrial energy metabolism, oxidative stress, calcium homeostasis and mitochondrial
dynamics in axons and the synapse, eventually leading to neuronal injury and cognitive
impairment. Therefore, the mitochondria are a very important target in the pathogenesis of
AD. Given the role of ABAD in Aβ-induced synaptic pathology, the development of small
molecules that inhibit the interaction of ABAD with Aβ, as outlined in this review, is a
novel innovative therapeutic strategy for the management of AD.
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Working Hypothesis. Interaction of ABAD with Aβ enhances generation/accumulation of
free radicals and impairs mitochondrial respiratory function. This leads to synaptic
dysfunction and aggravates cognitive dysfunction.
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Synaptic dysfunction caused by the ABAD-Aβ interaction. Binding of Aβ affects the
enzymatic function of ABAD, thereby causing unfavorable changes in lipid metabolism and
mitochondrial respiration. This ultimately leads to increased reactive oxygen species (ROS)
production and impaired calcium (Ca2+) retention and provokes the up-regulation of
peroxiredoxin-2 (Prx-2) and endophilin-1 (Ep-1). 1) Prx-2 is able to degrade ROS but its
function can be affected by elevated Ca2+ leading to its phosphorylation and inactivation
and the accumulation of ROS. 2) Ep-1 plays a role in glutamatergic (glut) synaptic
transmission by functioning in synaptic vesicle endocytosis, which is directly regulated by
Ca2+ binding to Ep-1 [80]. Ep-1 can also be involved in 3) JNK-activation as well as 4)
signaling events in the post-synapse leading to dendritogenesis. The correct balance of all of
these events in the synapse, which is disturbed by the ABAD-Aβ interaction, is of crucial
importance for synaptic plasticity and memory formation.
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The ABAD decoy peptide approach. Left: Levels of Aβ are elevated in the AD mouse
model (and the human AD brain), increasing its binding to loop D in ABAD. Endophilin-1
and peroxiredoxin-2 expression levels are increased in the AD mouse model as a result of
the ABAD-Aβ interaction, which also causes neuronal cellular stress (increased ROS
production, impaired metabolism, resulting in reduced plasma membrane integrity and
LDH-release and apoptosis). Right: Administration of modified peptides based to the loop D
amino acid sequence of ABAD are able to disrupt the ABAD-Aβ interaction in the AD
mouse model in vivo, decrease the expression of endophilin-1 and peroxiredoxin-2 and
restore cellular function and memory performance.
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